Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2014 1
2016 1
2017 1
2021 2
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Dorman SE, et al. N Engl J Med. 2021 May 6;384(18):1705-1718. doi: 10.1056/NEJMoa2033400. N Engl J Med. 2021. PMID: 33951360 Free PMC article. Clinical Trial.
CMV and HSV-2 myeloradiculitis in an HIV infected patient.
Pinto A, Santos E, Correa DF, Escada R, Vorsatz Cde M, Cardoso SW, Lima MA. Pinto A, et al. Among authors: escada r. Rev Inst Med Trop Sao Paulo. 2011 May-Jun;53(3):173-5. doi: 10.1590/s0036-46652011000300010. Rev Inst Med Trop Sao Paulo. 2011. PMID: 21755241 Free article. Review.
Determinants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis.
De Castro N, Chazallon C, N'takpe JB, Timana I, Escada R, Wagner S, Messou E, Eholie S, Bhatt N, Khosa C, Laureillard D, Do Chau G, Veloso VG, Delaugerre C, Anglaret X, Molina JM, Grinsztejn B, Marcy O; ANRS 12300 Reflate TB2 Study Group. De Castro N, et al. Among authors: escada r. Open Forum Infect Dis. 2022 Nov 19;9(12):ofac628. doi: 10.1093/ofid/ofac628. eCollection 2022 Dec. Open Forum Infect Dis. 2022. PMID: 36540390 Free PMC article.
Multidrug-resistant tuberculosis and culture conversion with bedaquiline.
Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RP, Dannemann B; TMC207-C208 Study Group. Diacon AH, et al. N Engl J Med. 2014 Aug 21;371(8):723-32. doi: 10.1056/NEJMoa1313865. N Engl J Med. 2014. PMID: 25140958 Free article. Clinical Trial.
Factors associated with prevalent Mycobacterium tuberculosis infection and disease among adolescents and adults exposed to rifampin-resistant tuberculosis in the household.
Kim S, Hesseling AC, Wu X, Hughes MD, Shah NS, Gaikwad S, Kumarasamy N, Mitchell E, Leon M, Gonzales P, Badal-Faesen S, Lourens M, Nerette S, Shenje J, de Koker P, Nedsuwan S, Mohapi L, Chakalisa UA, Mngqbisa R, Escada RODS, Ouma S, Heckman B, Naini L, Gupta A, Swindells S, Churchyard G; ACTG A5300/IMPAACT 2003 PHOENIx Feasibility Study Team. Kim S, et al. Among authors: escada rods. PLoS One. 2023 Mar 17;18(3):e0283290. doi: 10.1371/journal.pone.0283290. eCollection 2023. PLoS One. 2023. PMID: 36930628 Free PMC article.
Incidence and Predictors of Tuberculosis-associated IRIS in People With HIV Treated for Tuberculosis: Findings From Reflate TB2 Randomized Trial.
Coelho LE, Chazallon C, Laureillard D, Escada R, N'takpe JB, Timana I, Messou E, Eholie S, Khosa C, Chau GD, Cardoso SW, Veloso VG, Delaugerre C, Molina JM, Grinsztejn B, Marcy O, De Castro N. Coelho LE, et al. Among authors: escada r. Open Forum Infect Dis. 2024 Jan 22;11(3):ofae035. doi: 10.1093/ofid/ofae035. eCollection 2024 Mar. Open Forum Infect Dis. 2024. PMID: 38486816 Free PMC article. Clinical Trial.
Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.
De Castro N, Marcy O, Chazallon C, Messou E, Eholié S, N'takpe JB, Bhatt N, Khosa C, Timana Massango I, Laureillard D, Chau GD, Domergue A, Veloso V, Escada R, Wagner Cardoso S, Delaugerre C, Anglaret X, Molina JM, Grinsztejn B; ANRS 12300 Reflate TB2 study group. De Castro N, et al. Among authors: escada r. Lancet Infect Dis. 2021 Jun;21(6):813-822. doi: 10.1016/S1473-3099(20)30869-0. Epub 2021 Mar 2. Lancet Infect Dis. 2021. PMID: 33667406 Clinical Trial.
Impact of Larger Sputum Volume on Xpert® MTB/RIF Assay Detection of Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected Tuberculosis.
Badal-Faesen S, Firnhaber C, Kendall MA, Wu X, Grinsztejn B, Escada RODS, Fernandez M, Hogg E, Sanne I, Johnson P, Alland D, Mazurek GH, Benator DA, Luetkemeyer AF; AIDS Clinical Trials Group A5295; Tuberculosis Trials Consortium Study 34 Teams. Badal-Faesen S, et al. Among authors: escada rods. J Clin Med. 2017 Aug 7;6(8):78. doi: 10.3390/jcm6080078. J Clin Med. 2017. PMID: 28783093 Free PMC article.